Pro
-
Anti-trust authorities approve Bosch’s acquisition of Eisai Machinery
Bosch finalized the acquisition of the machinery business companies of Eisai, one of the leading Japanese pharmaceutical companies based in Tokyo. The transaction has been approved by the antitrust authorities without further restrictions.
Pro | 14 May 2012
-
Kuehne + Nagel launches innovative airfreight solution for pharmaceutical products
KN PharmaChain offers – among other features – door-to-door temperature control, a 24 hour alert system, optional wireless temperature measuring and best practice (GxP) standards for facilities, working processes and training programmes.
Pro | 08 May 2012
-
DKSH expands repackaging facility for healthcare products in Hong Kong
DKSH is expanding its repackaging facility for its healthcare business in Hong Kong to meet the growing needs of business partners.
Pro | 18 April 2012
-
Refinements in inhaled drug delivery enhances growth prospects as global markets emerge
Survey finds evolving device technologies creating opportunities for drug developers, according to Greystone Research Associates.
Pro | 10 April 2012
-
Espicom predicts new novel approaches to the treatment of cancer will be launched by 2018
According to an Espicom report, Targeted Cancer D: The launch landscape to 2018,the global cancer market could be set for rapid growth in key sectors, driven by increasingly un-met clinical need and the introduction of new drugs which effectively target new pathways.
Pro | 29 March 2012
-
Pharmaceutical circulation enterprises see relatively low profit margin in China
In China, pharmaceutical circulation enterprises see relatively low profit margin due to many circulation links. By sales value, some 20 percent of drugs are sold to consumers through pharmaceutical retail firms, and the rest (80 percent) are sold out through hospitals (including hospitals, community and township hospitals), according to Research and Markets.
Pro | 19 March 2012
-
Weak narcolepsy drug pipeline provides opportunities for pharma companies
The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing opportunities for drugs companies to expand into this market, a study by healthcare intelligence specialist GlobalData has found.
Pro | 07 March 2012
-
Merck receives European approval to expand use of Rebif
Merck announced that the European Commission (EC) has approved extension of the indication of Rebif (interferon beta-1a), its treatment for relapsing forms of multiple sclerosis (MS).
Pro | 02 March 2012
-
Biosimilars provide cost saving to users, industry
Biosimilars provide significant cost saving to both the users and the industry hence the adoption of these drugs are expected to be higher side.
Pro | 24 February 2012
-
BiondVax’s universal flu vaccine improves existing flu vaccines in elderly
BiondVax Pharmaceuticals announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly.
Pro | 20 February 2012
